Abstract
Purpose: To determine the biodistribution of Tc-99m labeled somatostatin receptor-binding peptide (Depreotide) on planar and SPECT studies of the thorax and upper abdomen in order to improve diagnostic accuracy.Methods and Materials: Retrospectively 29 planar and SPECT studies from 28 patients (all males, average age of 65.79) were reviewed. All the patients had been referred for evaluation of solitary pulmonary nodules. Two to four hours after IV injection of 555-to 740-MBq (15–20 mCi) Tc-99m Depreotide, anterior and posterior total body images, and anterior, posterior, right lateral and left lateral planar images were obtained, and thoracic SPECT was acquired with a three-head gamma camera. The degree of uptake in the lungs, thoracic cage, and organs of the upper abdomen was rated from “0” to “++++”.Results: The range of normal activity in the thorax includes cardiac, “0”; pulmonary, “+”; rib, “+/++”; sternum, “++”; vertebrae, “++”. The degree of normal activity seen in the upper abdominal organs includes liver and spleen, “+++”, and kidneys, “+++/++++”. Eight patients with emphysema had diffuse pulmonary uptake graded as “+/++”. One patient with left pneumonectomy and radiation therapy to the left hemithorax had photon-deficiency in the left hemithorax and decreased to absent uptake including the vertebrae and ribs. Although some cases had background pulmonary uptake of Tc-99m Depreotide, the bone/bone marrow activity of the thoracic cage including the ribs, sternum, and thoracic spine is sufficiently great enough to produce a clear distinction between bone and lung in the thoracic cavity that gives high-contrast resolution on SPECT.Conclusions: The intensity of radioactivity in the sub-diaphragmatic organs such as the liver, spleen, and kidneys provides useful guidance for the categorization of pulmonary lesions. The uptake of land marks such as the sternum, which is anteriorly located, and the thoracic vertebrae, which are posteriorly located in the thoracic cage, can be used in the localization of a Depreotide avid tumor.
Similar content being viewed by others
References
Blum J, Handmaker H, Lister-James J, Rinne NA, and the NeoTect solitary pulmonary nodule study group. A multicenter trial with a somatostatin analog Tc-99m depreotide in the evaluation of solitary pulmonary nodules.Chest 2000; 117: 1232–1238.
Blum J, Handmaker H, Rinne NA. The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules.Chest 1999; 115: 224–232.
Kernstine KH, Kahn D, Menda Y, Bushnell D, Mclaughlin K, Milller S, Rossi N. A New Technique for Staging Potentially-Resectable Lung Cancer: Tc-99m NeoTec SPECT compared with F-18 FDG. Proceedings of theAmerica Society of Clinical Oncology Vol. 20 Part 1 of 2 (1352), 2001.
Spagnolo SV. The diagnostic strategy for lung cancer: Has determining malignancy or benignity become more accurate? (Editorial)Chest 2000; 117: 1219–1220.
Morehead RS, Shih WJ. Tc-99m Labeled Somatostatin Receptor-binding Peptide Imaging for a Pulmonary Nodule.Clin Nucl Med 2001; 26: 910–912.
NeoTect package insert (NeoTect Prescribing Information). Revised October 1999; Rentschler Biotechnologie GmbH&Co. KG, Laupheim, Germay for Diatide, Inc Londonderry, New Hamsphire, 03053 USA.
Handmaker H, Mohler K, Dann R, et al. Oncoscintigraphy of neuroendocrine and non-neuroendocrine tumors with a novel ssr binding peptide Tc-99m P829-preliminary experience in 39 patients. (abstract)Clin Nucl Med 1997; 22: 350.
Vallabhajosula S, Moyer B, Lister-James, et al. Preclinical evaluation of Tc-99m labeled somatostatin receptor-binding peptides.J Nucl Med 1996; 37: 1016–1022.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shih, WJ., Hirschowitz, E., Bensadoun, E. et al. Biodistribution on Tc-99m labeled somatostatin receptor-binding peptide (Depreotide, NeoTec) planar and SPECT studies. Ann Nucl Med 16, 213–219 (2002). https://doi.org/10.1007/BF02996303
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02996303